Inebilizumab for Treatment of IgG4-Related Disease
New England Journal of Medicine · 27.03.2025 · 392 (12) · 1168-1177
DOI: 10.1056/nejmoa2409712 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 27.03.2025. Verfasst von John H Stone und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Amgen Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston.
- Division of Rheumatology, Emory University School of Medicine, Atlanta.
- Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing.
- Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan.
- Department of Internal Medicine, Kansai Medical University Kori Hospital, Osaka, Japan.
- First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
ORCID-Profile: Yoshiya Tanaka, Daniel Cimbora
Förderung
- Amgen Foundation
Zitieren
APA
Stone, J. H., Khosroshahi, A., Zhang, W., Della Torre, E., Okazaki, K., Tanaka, Y., Löhr, J. M., Schleinitz, N., Dong, L., Umehara, H., Lanzillotta, M., Wallace, Z. S., Ebbo, M., Webster, G. J., Martinez Valle, F., Nayar, M. K., Perugino, C. A., Rebours, V., Dong, X., …, & MITIGATE Trial Investigators (2025). Inebilizumab for Treatment of IgG4-Related Disease. New England Journal of Medicine, 392(12), 1168-1177. https://doi.org/10.1056/nejmoa2409712
Vancouver
Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al. Inebilizumab for Treatment of IgG4-Related Disease. New England Journal of Medicine. 2025;392(12):1168-1177. doi:10.1056/nejmoa2409712
BibTeX
@article{Stone2025,
author = {Stone, John H and Khosroshahi, Arezou and Zhang, Wen and Della Torre, Emanuel and Okazaki, Kazuichi and Tanaka, Yoshiya and Löhr, J Matthias and Schleinitz, Nicolas and Dong, Lingli and Umehara, Hisanori and Lanzillotta, Marco and Wallace, Zachary S and Ebbo, Mikael and Webster, George J and Martinez Valle, Fernando and Nayar, Manu K and Perugino, Cory A and Rebours, Vinciane and Dong, Xinxin and Wu, Yanping and Li, Qing and Rampal, Nishi and Cimbora, Daniel and Culver, Emma L and MITIGATE Trial Investigators, MITIGATE Trial Investigators},
title = {Inebilizumab for Treatment of IgG4-Related Disease},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {12},
pages = {1168--1177},
doi = {10.1056/nejmoa2409712}
}
EUVIMED